about
The APJ receptor: a new therapeutic approach in diabetic treatmentApelin stimulates glucose utilization in normal and obese insulin-resistant miceApelin treatment increases complete Fatty Acid oxidation, mitochondrial oxidative capacity, and biogenesis in muscle of insulin-resistant mice.Apelin and energy metabolism.Expanding role for the apelin/APJ system in physiopathology.Effect of hypocaloric diet-induced weight loss in obese women on plasma apelin and adipose tissue expression of apelin and APJ.Effects of dietary eicosapentaenoic acid (EPA) supplementation in high-fat fed mice on lipid metabolism and apelin/APJ system in skeletal muscle.Apelin, diabetes, and obesity.Apelin, a promising target for type 2 diabetes treatment?Apelin receptors: From signaling to antidiabetic strategy.Apelin administration improves insulin sensitivity in overweight men during hyperinsulinaemic-euglycaemic clamp.TNFalpha up-regulates apelin expression in human and mouse adipose tissue.Regulation of secreted protein acidic and rich in cysteine during adipose conversion and adipose tissue hyperplasia.Human alpha 2A-adrenergic receptor gene expressed in transgenic mouse adipose tissue under the control of its regulatory elements.Adipokine expression profile in adipocytes of different mouse models of obesity.Chronic apelin treatment improves hepatic lipid metabolism in obese and insulin-resistant mice by an indirect mechanism.Lipolysis is altered in MHC class I zinc-alpha(2)-glycoprotein deficient mice.Modifications of mesenteric adipose tissue during moderate experimental colitis in mice.Is Crohn's creeping fat an adipose tissue?Decreased Resistin Expression in Mice with Different Sensitivities to a High-Fat DietCentral Apelin Controls Glucose Homeostasis via a Nitric Oxide-Dependent Pathway in Mice[Development of nutritional obesity in transgenic mice with an adrenergic receptivity in adipose tissue comparable with that of humans]The intestinal glucose-apelin cycle controls carbohydrate absorption in miceThe apelin/APJ system as a therapeutic target in metabolic diseases
P50
Q27025069-F815F4DD-9D6B-4E1F-A50E-32227063CD59Q28302298-402B3EB6-3723-4A13-BEF7-0BA2BDA914EDQ34030044-DD91F50F-2343-4981-BBFB-BE09A675B146Q35352250-64BADF3D-64D8-4436-8E51-F44F164C4E39Q37154640-630ED34B-BCA0-47EE-A3B4-85D4E6DEE966Q37194593-030E211F-4618-4342-9F4A-F6C9E3848A2BQ37288696-1E9E4E4D-6F97-43C3-ABAA-56DE81CDCED6Q37897155-5CBF4CAA-27B9-45B5-82DC-5EF45095595DQ37996726-52FBF79F-6A20-44E5-80AE-30347CB10904Q38501605-AC10408D-C044-4892-9918-ACA4ECB16EBBQ38691457-D7322BF3-BC56-4EEB-B0E7-3B6ED4D0E328Q42801394-559D6E0A-6097-4E23-9202-926A8F81BE4CQ42833163-0C664A22-32C5-47C0-887D-156816A13927Q44172038-BF07ED3A-435B-41F4-B5B2-FFB046558386Q46863868-46588011-3BEF-4A1F-A30A-80372F811600Q48042174-2B1C7DC6-68A0-4618-B591-7C2128B1905FQ51800510-96282528-001C-45D0-AA58-3EA03E518C77Q54236253-ACD1C325-07FD-49A5-B9A1-5AAA0A23530EQ54416901-383F161A-27D8-47AE-945E-E4CF6DF7F746Q60265323-3219B637-926F-4A98-A8EE-15A981DA5C5CQ60843013-50F324E3-F948-4BF5-BDCC-8293F2AA736CQ77715115-47ABCC94-D435-44FD-9F19-66D1B096B45EQ85892132-86C4CCA8-7E6D-4153-89E2-66CA3EB52E5BQ90662471-21F9F2C3-E6C1-4C55-820F-644C4AFEF440
P50
description
researcher
@en
wetenschapper
@nl
name
Castan-Laurell I
@nl
Isabelle Castan-Laurell
@en
type
label
Castan-Laurell I
@nl
Isabelle Castan-Laurell
@en
altLabel
Castan-Laurell I
@en
prefLabel
Castan-Laurell I
@nl
Isabelle Castan-Laurell
@en
P106
P31
P496
0000-0002-0488-9789